Theratechnologies Stock Today
| TH Stock | CAD 2.26 0.05 2.16% |
PerformanceVery Weak
| Odds Of DistressLow
|
Theratechnologies is selling at 2.26 as of the 20th of March 2025; that is 2.16% down since the beginning of the trading day. The stock's open price was 2.31. Theratechnologies has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. The company was founded in 1993 and is headquartered in Montreal, Canada. THERATECHNOLOGIES operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. The company has 45.98 M outstanding shares of which 3.88 K shares are at this time shorted by private and institutional investors with about 0.07 days to cover all short positions. More on Theratechnologies
Moving together with Theratechnologies Stock
Moving against Theratechnologies Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Theratechnologies Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Theratechnologies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Theratechnologies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Paul Lvesque | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
Theratechnologies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Theratechnologies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsTheratechnologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Theratechnologies' financial leverage. It provides some insight into what part of Theratechnologies' total assets is financed by creditors.
| |||||
Theratechnologies (TH) is traded on Toronto Exchange in Canada and employs 26 people. Theratechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 103.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Theratechnologies's market, we take the total number of its shares issued and multiply it by Theratechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Theratechnologies classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 45.98 M outstanding shares of which 3.88 K shares are at this time shorted by private and institutional investors with about 0.07 days to cover all short positions.
Theratechnologies has accumulated about 9.21 M in cash with 2.38 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35.
Check Theratechnologies Probability Of Bankruptcy
Ownership AllocationTheratechnologies shows a total of 45.98 Million outstanding shares. Over half of Theratechnologies' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Theratechnologies. Please watch out for any change in the institutional holdings of Theratechnologies as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Theratechnologies Ownership Details
Theratechnologies Risk Profiles
Although Theratechnologies' alpha and beta are two of the key measurements used to evaluate Theratechnologies' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.23 | |||
| Semi Deviation | 4.44 | |||
| Standard Deviation | 4.52 | |||
| Variance | 20.44 |
Theratechnologies Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Theratechnologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
Theratechnologies Corporate Directors
| Sheila Frame | Independent Director | Profile | |
| Gerald Lacoste | Independent Director | Profile | |
| Paul Pommier | Independent Director | Profile | |
| Gilles Cloutier | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.